Market revenue in 2023 | USD 707.9 million |
Market revenue in 2030 | USD 669.2 million |
Growth rate | -0.8% (CAGR from 2023 to 2030) |
Largest segment | Antiemetics |
Fastest growing segment | NSAIDs and Others |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Antiemetics was the largest segment with a revenue share of 28.11% in 2023. Horizon Databook has segmented the Latin America cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
Latin America cancer supportive care drugs market is characterized by growing cancer patient population due to a combination of demographic, environmental, and socioeconomic problems. It is estimated that by 2030, around 1.7 million individuals will have been diagnosed with cancer, and more than 1 million deaths will occur every year due to cancer in this region. Moreover, the estimated prevalence of cancer pain in this region ranges from around 43% to 63%.
Furthermore, 2017 research studies show that approximately 5.7 million individuals have little to no access to analgesic opioid drugs. The level of cancer care differs across countries based on the level of public funding for healthcare. Individuals living in countries such as Brazil, which provides free public health services, have wider access to cancer care supportive drugs. They are covered under the public healthcare system.
Other countries such as Argentina have approved cancer care supportive drugs; however, a wide-scale benefit is not delivered due to larger population, lack of adequate planning for cancer care at national level, regional differences in the levels of care, and unequal coverage across different insurance providers. However, owing to growing awareness about cancer among leading countries in Latin America, the level of cancer supportive care is expected to improve in the coming years, which may drive market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America cancer supportive care drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account